Metformin-loaded Nanoparticles Reduce Hyperglycemia-associated Oxidative Stress and Induce ENOS Phosphorylation in Vascular Endothelial Cells

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 27

PMID 39730492

Authors

Hana A Mohamed

Nura A Mohamed

Shantelle S Macasa

Hamda K Basha

Adna M Adan

Sergio Crovella

Hong Ding

Christopher R Triggle

Isra Marei

Haissam Abou-Saleh

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus is a chronic disease characterized by metabolic defects, including insulin deficiency and resistance. Individuals with diabetes are at increased risk of developing cardiovascular complications, such as atherosclerosis, coronary artery disease, and hypertension. Conventional treatment methods, though effective, are often challenging, costly, and may lead to systemic side effects. This study explores the potential of nanomedicine applications, specifically Metal-Organic Frameworks (MOFs), as drug carriers to overcome these limitations. The Materials Institute Lavoisier-89 nanoparticles (nanoMIL-89) have previously demonstrated promise as a drug delivery vehicle for chronic diseases due to their anti-oxidant and cardio-protective properties. In this investigation, nanoMIL-89 was loaded with the anti-diabetic drug metformin (MET), creating MET@nanoMIL-89 formulation. We examined the drug release kinetics of MET@nanoMIL-89 over 96 h and assessed its impact on the viability of various endothelial cells. Furthermore, we investigated the nanoformulation effect on the inflammatory marker CXCL8 in these cells and explored its influence on phosphorylated eNOS, total eNOS, and AKT levels. Our findings indicate that nanoMIL-89 effectively released metformin over 96 h and caused a concentration-dependent reduction in CXCL8 release from endothelial cells. Notably, MET@nanoMIL-89 reduced dihydroethidium levels and increased phosphorylated eNOS, total eNOS, and AKT levels. Our results underscore the potential of nanoMIL-89 as a versatile potential drug delivery platform for anti-diabetic drugs, offering a prospective therapeutic approach for diabetic patients with associated cardiovascular complications.

References

Tucker G, Casey C, Phillips P, Connor H, Ward J, Woods H . Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; 12(2):235-46. PMC: 1401849. DOI: 10.1111/j.1365-2125.1981.tb01206.x. View

Cutiongco M, Chua B, Neo D, Rizwan M, Yim E . Functional differences between healthy and diabetic endothelial cells on topographical cues. Biomaterials. 2017; 153:70-84. PMC: 5724387. DOI: 10.1016/j.biomaterials.2017.10.037. View

Abernethy A, Stackhouse K, Hart S, Devendra G, Bashore T, Dweik R . Impact of diabetes in patients with pulmonary hypertension. Pulm Circ. 2015; 5(1):117-23. PMC: 4405710. DOI: 10.1086/679705. View

Hadi H, Suwaidi J . Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2008; 3(6):853-76. PMC: 2350146. View

Sankhyan A, Pawar P . Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization. Daru. 2013; 21(1):7. PMC: 3556082. DOI: 10.1186/2008-2231-21-7. View

Sakao S, Tatsumi K, Voelkel N . Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res. 2009; 10:95. PMC: 2768704. DOI: 10.1186/1465-9921-10-95. View

Mohamed N, Abou-Saleh H, Kameno Y, Marei I, De Nucci G, Ahmetaj-Shala B . Studies on metal-organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension. Sci Rep. 2021; 11(1):4336. PMC: 7900107. DOI: 10.1038/s41598-021-83423-6. View

Moghassemi S, Parnian E, Hakamivala A, Darzianiazizi M, Mowlavi Vardanjani M, Kashanian S . Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater Sci Eng C Mater Biol Appl. 2014; 46:333-40. DOI: 10.1016/j.msec.2014.10.070. View

Kenechukwu F, Isaac G, Nnamani D, Momoh M, Attama A . Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions. Heliyon. 2022; 8(3):e09100. PMC: 8933683. DOI: 10.1016/j.heliyon.2022.e09100. View

10.

Ebrahimi H, Javadzadeh Y, Hamidi M, Jalali M . Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. Daru. 2015; 23:46. PMC: 4578325. DOI: 10.1186/s40199-015-0128-3. View

11.

Kesharwani P, Gorain B, Low S, Tan S, Ling E, Lim Y . Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res Clin Pract. 2017; 136:52-77. DOI: 10.1016/j.diabres.2017.11.018. View

12.

Hanato J, Kuriyama K, Mizumoto T, Debari K, Hatanaka J, Onoue S . Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect. Int J Pharm. 2009; 382(1-2):111-6. DOI: 10.1016/j.ijpharm.2009.08.013. View

13.

Wang W, Yan X, Li Q, Chen Z, Wang Z, Hu H . Adapted nano-carriers for gastrointestinal defense components: surface strategies and challenges. Nanomedicine. 2020; 29:102277. DOI: 10.1016/j.nano.2020.102277. View

14.

Raza A, Wu W . Metal-organic frameworks in oral drug delivery. Asian J Pharm Sci. 2024; 19(5):100951. PMC: 11530798. DOI: 10.1016/j.ajps.2024.100951. View

15.

Joshi H, Bhumkar D, Joshi K, Pokharkar V, Sastry M . Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir. 2005; 22(1):300-5. DOI: 10.1021/la051982u. View

16.

Pereira A, Brito G, Lima M, da Silva Junior A, Dos Santos Silva E, Rezende A . Metformin Hydrochloride-Loaded PLGA Nanoparticle in Periodontal Disease Experimental Model Using Diabetic Rats. Int J Mol Sci. 2018; 19(11). PMC: 6274734. DOI: 10.3390/ijms19113488. View

17.

Al-Ansari D, Mohamed N, Marei I, Zekri A, Kameno Y, Davies R . Internalization of Metal-Organic Framework Nanoparticles in Human Vascular Cells: Implications for Cardiovascular Disease Therapy. Nanomaterials (Basel). 2020; 10(6). PMC: 7353612. DOI: 10.3390/nano10061028. View

18.

Graham G, Punt J, Arora M, Day R, Doogue M, Duong J . Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50(2):81-98. DOI: 10.2165/11534750-000000000-00000. View

19.

Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T . Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater. 2009; 9(2):172-8. DOI: 10.1038/nmat2608. View

20.

Alai M, Lin W, Pingale S . Application of polymeric nanoparticles and micelles in insulin oral delivery. J Food Drug Anal. 2017; 23(3):351-358. PMC: 9351800. DOI: 10.1016/j.jfda.2015.01.007. View